COSCIENS Biopharma Inc. Common Stock
CSCI
CSCI was delisted on the 3rd of September, 2025.
15 hedge funds and large institutions have $824K invested in COSCIENS Biopharma Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 5 closing their positions.
21% more capital invested
Capital invested by funds: $681K → $824K (+$143K)
0% more ownership
Funds ownership: 0.02% → 0.02% (+0%)
17% less funds holding
Funds holding: 18 → 15 (-3)
23% less call options, than puts
Call options by funds: $106K | Put options by funds: $137K
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$101K |
| 2 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$70.8K |
| 3 |
JP Morgan Chase
New York
|
+$39.3K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$18.1K |
| 5 |
Citigroup
New York
|
+$2.08K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$42K |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$30.6K |
| 3 |
PCM
Prelude Capital Management
New York
|
-$22K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$21.4K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$17.1K |
CSCI Hedge Fund Activity: Q4 2017 in Review
15 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q4 2017, worth a combined $824K — up 21% from $681K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CSCI and 3 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 3 added.
The largest buyer was Morgan Stanley, adding an estimated $101K. The largest seller was Private Advisor Group, exiting entirely with an estimated $42K sold.
- 15 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q4 2017, down from 18 in Q3 2017.
- Funds reported $824K of COSCIENS Biopharma Inc. Common Stock stock for Q4 2017, up 21% quarter-over-quarter.
- 3 funds opened new COSCIENS Biopharma Inc. Common Stock positions in Q4 2017 and 5 closed out, a net change of -2 holders.
- The largest COSCIENS Biopharma Inc. Common Stock buyer in Q4 2017 was Morgan Stanley, an estimated $101K added.
- The largest COSCIENS Biopharma Inc. Common Stock seller in Q4 2017 was Private Advisor Group, an estimated $42K sold.
Based on aggregated 13F filings for Q4 2017.